X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA ELDER PHARMA SHASUN PHARMA/
ELDER PHARMA
 
P/E (TTM) x 123.9 -0.2 - View Chart
P/BV x 8.5 0.1 8,455.4% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SHASUN PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
ELDER PHARMA
Jun-14
SHASUN PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs94380 24.8%   
Low Rs46188 24.3%   
Sales per share (Unadj.) Rs214.2491.2 43.6%  
Earnings per share (Unadj.) Rs5.3-3.2 -167.7%  
Cash flow per share (Unadj.) Rs15.814.4 109.8%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.3376.5 14.2%  
Shares outstanding (eoy) m56.6220.54 275.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.30.6 56.4%   
Avg P/E ratio x13.1-89.3 -14.7%  
P/CF ratio (eoy) x4.419.7 22.4%  
Price / Book Value ratio x1.30.8 173.7%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,9585,833 67.8%   
No. of employees `000NANA-   
Total wages/salary Rs m2,1642,179 99.3%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m12,12710,089 120.2%  
Other income Rs m229257 89.4%   
Total revenues Rs m12,35610,346 119.4%   
Gross profit Rs m1,009-792 -127.4%  
Depreciation Rs m594361 164.3%   
Interest Rs m4152,756 15.1%   
Profit before tax Rs m230-3,653 -6.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m-73125 -58.1%   
Profit after tax Rs m302-65 -462.3%  
Gross profit margin %8.3-7.8 -106.0%  
Effective tax rate %-31.7-3.4 924.1%   
Net profit margin %2.5-0.6 -384.6%  
BALANCE SHEET DATA
Current assets Rs m6,8849,240 74.5%   
Current liabilities Rs m8,4569,998 84.6%   
Net working cap to sales %-13.0-7.5 172.6%  
Current ratio x0.80.9 88.1%  
Inventory Days Days6246 133.1%  
Debtors Days Days10860 179.4%  
Net fixed assets Rs m4,97010,124 49.1%   
Share capital Rs m113206 55.1%   
"Free" reserves Rs m2,8755,582 51.5%   
Net worth Rs m3,0207,734 39.1%   
Long term debt Rs m1,8174,889 37.2%   
Total assets Rs m13,34722,882 58.3%  
Interest coverage x1.6-0.3 -477.5%   
Debt to equity ratio x0.60.6 95.2%  
Sales to assets ratio x0.90.4 206.1%   
Return on assets %5.411.8 45.7%  
Return on equity %10.0-0.8 -1,183.8%  
Return on capital %13.322.3 59.7%  
Exports to sales %46.43.0 1,525.4%   
Imports to sales %14.20.4 3,335.0%   
Exports (fob) Rs m5,622307 1,833.5%   
Imports (cif) Rs m1,72843 4,008.6%   
Fx inflow Rs m5,843307 1,905.6%   
Fx outflow Rs m2,173125 1,734.3%   
Net fx Rs m3,669181 2,024.0%   
CASH FLOW
From Operations Rs m39811,754 3.4%  
From Investments Rs m-1,635-561 291.7%  
From Financial Activity Rs m1,309-6,762 -19.4%  
Net Cashflow Rs m714,432 1.6%  

Share Holding

Indian Promoters % 39.2 39.6 99.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 7.5 48.0%  
FIIs % 17.6 16.8 104.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 36.1 109.7%  
Shareholders   20,750 16,479 125.9%  
Pledged promoter(s) holding % 12.3 77.6 15.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   PIRAMAL ENTERPRISES  GSK PHARMA  DR. DATSONS LABS  DR. REDDYS LAB  NOVARTIS  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS